SCHEMBL5752891

SCHEMBL5752891

COc1ccc(Br)cc1C(O)c1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.43
LMNA P02545 2/20 0.43
TOP2A P11388 1/20 0.40
TOP2B Q02880 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ADRA2A P08913 2/20 0.39
ADRA1A P35348 2/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
CYP2D6 P10635 1/20 0.38
LPAR1 Q92633 1/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
IGF1R P08069 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442604 0.88 LMNA (0.38) LMNATOP2ATOP2BADRA2AADRA1A
SCHEMBL20140072 0.84 KMT2A (0.40) HPGDLMNATOP2ATOP2BKMT2A
SCHEMBL1456831 0.81 HPGD (0.34) HPGDLMNATOP2ATOP2BKMT2A
SCHEMBL3988110 0.80 ADRA2A (0.45) HPGDLMNAKMT2AKDM4EADRA2A
SCHEMBL7426724 0.80 ADRA2A (0.45) HPGDLMNAKMT2AKDM4EADRA2A
SCHEMBL12782153 0.78 LMNA (0.46) LMNATOP2ATOP2BKMT2AADRA2A
SCHEMBL82671 0.76 ADRA1A (0.50) LMNAKMT2AKDM4EADRA2AADRA1A
SCHEMBL3917312 0.76 LPAR1 (0.49) LMNAKDM4ECYP2D6LPAR1GAA
SCHEMBL2061830 0.76 GAA (0.41) LMNAKMT2AKDM4ELPAR1MGAM
SCHEMBL4671160 0.75 MAPT (0.42) HPGDKMT2AKDM4EADRA2AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379234-B1 HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF NOVARTIS AG (CH) 2006-03-29 EP disclosed
US-6919336-B2 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF NOVARTIS AG (CH) 2005-07-19 US disclosed
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf NOVARTIS AG (CH) 2004-05-20 US disclosed
EP-1379234-A1 HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF Novartis AG (CH) 2004-01-14 EP disclosed
WO-2002076447-A1 HALLOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF NOVARTIS AG (CH) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf TNF, NFKBIA, IL1A HPGD 95/4885LMNA 2179/4885TOP2A 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.